The aim of the study was to describe the temporal trends in the incidence of Kaposi's sarcoma (KS) in black South Africans in KwaZulu-Natal (KZN). The study was designed as a retrospective record review. The incidence of Kaposi's sarcoma was estimated using administrative records for patients receiving care for KS through public sector oncology clinics in KZN, 1983KZN, -2006 Annual age-standardized incidence rates were calculated using provincial census data for the denominator. Age-specific rates were calculated for the pre-AIDS (1983)(1984)(1985)(1986)(1987)(1988)(1989) and for the generalized AIDS epidemic eras (2006). Age-standardized incidence of KS increased in KZN from ,1:100,000 in 1990 to at least 15:100,000 in 2006; this increase was observed in both men and women. There was a shift in the peak age-specific incidence rates from the sixth decade of life in the pre-AIDS era to the fourth and fifth decades in the AIDS era. In conclusion, KS is a growing public health problem in KZN, South Africa. These data reinforce the need for comprehensive national access to and roll-out of antiretroviral drugs, given their success in prevention and treatment of KS in first-world settings.
INTRODUCTION
In countries with generalized HIV epidemics and high prevalence of the Kaposi's sarcoma-associated herpes virus (KSHV), HIV-associated Kaposi's sarcoma (KS) is an important public health concern. In Uganda and Zimbabwe, countries with population-based cancer registries, the incidence of KS increased dramatically with increasing HIV prevalence to become the commonest malignancy in men and second commonest in women. 1 -3 Between 1988 and 1996, early years of the HIV epidemic in South Africa, the incidence of histologically confirmed KS in South Africa tripled. 4 Following this, data from the South African National Cancer Registry showed that KS increased from the 13th ranked cancer in men and 15th ranked cancer in women in 1998 to seventh most common cancer in men and 11th ranked cancer in women in 1999. However, in 1999 the age-standardized incidence rates of 2.4 per 100,000 in black men and 1.5 per 100,000 in black women 5 were dramatically lower than in Uganda 2,6 during the same period. There is no published data on the incidence of KS in South Africa after 1999; however, there is reason for concern of a growing burden of this HIV-associated malignancy.
An estimated 5.4 million South Africans are HIV infected. 7 The national HIV antenatal clinic seroprevalence rate was 29% in 2006, with a regional rate of 39% in KwaZulu-Natal (KZN) province. 8 Furthermore, KSHV infection is endemic in South Africa, with estimates of seroprevalence dependent on the assay used and the population sampled. Hospital-based estimates of KSHV seroprevalence in black South Africans adults range from 32% 9 to 62.8%. 10 Crosssectional community sampling in both urban and rural KZN demonstrates rates of 6% throughout early childhood 9 that increases with age to approximately 40% by the sixth decade of life. 11 USA data demonstrated that prior to the widespread introduction of combination antiretroviral (ARV) therapy, 50% of men with dual infection with HIV and KSHV developed KS within 10 years, 12 and that the incidence of KS decreased dramatically after the introduction of ARV therapy in 1996. 13 Given the lack of data on the incidence of KS in South Africa since 1999, despite worsening of the HIV epidemic, we have estimated KS incidence in KZN over time, and compared this with HIV seroprevalence data available through the South African Department of Health antenatal clinic HIV surveillance. Such data can help estimate the public health impact of HIV prevalence on the development of HIV-associated malignancies, and allow for planning of interventions to address HIV-associated KS. Both prevention and treatment planning depend on timely epidemiologic data.
METHODS
We performed a retrospective record review of patients with KS from all public sector oncology referral clinics (King Edward VIII, Addington, Inkosi Albert Luthuli and Greys Hospitals) in the province of KZN between 1983 and 2006. Data collected included date of initial appointment, histologic diagnosis, age at diagnosis, gender and district of residence; names were not recorded. Incident cases were defined as patients with histologically confirmed KS upon their initial visit. HIV status was not available for most of the cases. Given the HIV epidemic in KZN disproportionately affects black South Africans, only incident cases of KS in black South Africans were included. Annual age-specific incidence rates were calculated using the number of observed cases in each five-year age group as the numerator. The mid-year black population data for KZN in the same five-year age groups (denominator) were obtained from the national census surveys carried out in South Africa in 1985, 1996, 2001 and 2006 and data for the intervening years were interpolated. The world standard population data in the same five-year age groups were used to calculate the age-standardized incidence rates by the direct method, 6 the same methods utilized by the South African Nation Cancer Registry to enable comparison with other standardized rates free from the distortion that arises from different age structures in different populations and at different times. 5 Age-specific rates were calculated for the period 1983-1989, representing rates prior to the generalized HIV epidemic, as well as in 2006, during the peak of the HIV epidemic in KZN. HIV prevalence reported from 1991 to 2006 was obtained from the annual national antenatal clinic (ANC) seroprevalence surveys, which provide the best estimate of longitudinal trends in HIV infection, using a uniform methodology over 15 years. Comparisons of antenatal clinic surveillance with national population-based surveys suggest the former overestimate HIV prevalence in the general population by about 20%; however, ANC data provide an important estimate of the trends in HIV prevalence within the setting of a generalized epidemic. 14 Graphs were created using Stata IC 10.0 for Macintosh (College Station, TX, USA). This study was approved by the University of Natal Ethics committee (approval number H029/02). Over this time period, a dramatic temporal increase in the incidence of KS was observed in the general black population in KZN. Between 1983 and 2006, age-standardized incidence rates in men increased almost 20-fold from 1.0 to 19.7 cases per 100,000, while in women they increased 50-fold from 0.2 to 11.51 cases per 100,000, thus narrowing the male preponderance in incidence over time. The estimated male to female ratios prior to the AIDS epidemic were unstable owing to small sample sizes in each year (data not shown) but suggest that in the pre-AIDS era, between four and five men for every woman sought treatment for KS through the public sector, while the current ratio of men to women is less than 2. The increase for the combined sexes was from 0.5 to 14.8 cases per 100,000 (Figure 1 ). This increase mirrors that of HIV Figure 1 Age-standardized incidence ratio per 100,000 population of Kaposi's sarcoma (KS) over a 23-year period 1983 -2006 in black South Africans. (A) Age-standardized incidence in women, (B) age-standardized incidence in men and (C) age-standardized incidence in combined sexes (total) presenting at the major referral hospitals in KwaZulu-Natal (KZN) compared with the background HIV prevalence among antenatal clinic attendees in KZN, South Africa seroprevalence for KZN, which increased steadily from 1.6% in 1989 to 39% in 2006. As seen in Uganda, there was a shift of peak incidence in both men and women in the fourth and fifth decades of life when HIV was prevalent, compared with a peak incidence between ages 55 -60 in the pre-HIV era (1983) (1984) (1985) (1986) (1987) (1988) (1989) (Figure 2 ). The mean age of patients with KS declined significantly from 59.7 years (standard deviation [SD] 8.1) in 1983 to 36.5 years (SD 9.9) in 2006.
RESULTS

DISCUSSION
The estimates of KS incidence presented here, while significantly higher than those that the South African National Cancer Registry last reported for 1999, are likely to be underestimations of the true incidence rate. Several limitations to our methodology exist, and would bias towards an underestimate of the true incidence in KZN. Referral bias is expected, as only patients requiring therapy for KS are referred to the clinics and included in the records used in our analysis. Patients with either very early-or late-stage KS would likely have been referred for ARVs or palliation, respectively, without referral to an oncology clinic for radiation and chemotherapy. In addition, KS sometimes goes undiagnosed, as the asymptomatic early patches and plaques of KS are very likely to go unnoticed by patients and health-care professionals, especially in dark-skinned individuals. 16 Lastly, private sector patients are by definition not included in this analysis.
Differences in methodology between this study, in which incidence estimates are based on treatment patterns of histologically confirmed KS presenting to public oncology clinics, and those of neighbouring countries like Zimbabwe and Uganda, in which incident cases are determined through populationbased cancer registries, should be noted.
Despite these limitations, this study confirms that KS is an increasing public health concern in KZN, South Africa. The increasing incidence of KS is most likely due to the increasing magnitude of the HIV-infected population at risk of developing this HIV-associated malignancy in KZN. Furthermore, as in other sub-Saharan countries with HIV-associated KS epidemics, KS in KZN has become a disease that affects both younger men and women. The future trends in KS incidence in South Africa will depend on several factors. On the one hand, KS incidence is often associated with advanced immunosuppression, and KS incidence may lag behind HIV incidence by at least five years. On the other hand, increasing availability of ARVs may prevent a proportion of new cases, and the impact of governmental ARV roll-out programmes on KS in South Africa has the potential for both substantial prevention and clinically significant improvements in survival among patients diagnosed with HIV-associated KS. 17 South African government sponsored roll-out of ARVs to patients with AIDS began in 2003. While advances in ARV treatment have been made, in 2006, still only 23% of those with World Health Organization stage IV HIV in KZN were receiving ARV therapy. Nearly 1.4 million people in KZN province are estimated to be HIV infected but are not receiving ARVs due to early disease, lack of access or lack of knowledge of HIV status. 18 As the HIV epidemic matures in South Africa, additional methodologies to capture the impact of HIV on rates of cancer in South Africa are needed. Analyses of temporal trends in KS incidence are essential to examine the impact of the implementation of the governments' national ARV roll-out and inform policy in a country ravaged by HIV/ AIDS. As has been documented in the USA and Europe after the implementation of highly active antiretroviral therapy, we are hopeful that KS incidence will decline in South Africa as the national ARV roll-out programme expands. KS is the commonest malignancy associated with HIV, hence these data are vital to inform future research, optimize clinical management and allocate financial resources.
CONCLUSION
The increasing incidence of KS in the black population of KZN, South Africa presenting to public sector oncology clinics is a growing public health concern. It affects both men and women at a younger age due to the relentless HIV epidemic. We remain hopeful that widespread availability of ARV therapy will reduce the incidence of AIDS-associated KS in South Africa. However, with the limited access and slow roll-out of ARV therapy in South Africa the shift in trend towards declining KS incidence is still a pipedream, and new prevention and treatment strategies are urgently needed.
